N-(2-methoxyethyl)-N-methylpiperidin-4-amine | 885675-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(2-methoxyethyl)-N-methylpiperidin-4-amine
• CAS: 885675-71-8
• 化学式: C₉H₂₀N₂O
• 分子量: 172.27
• InChiKey: UOZUNDRVESAZLS-UHFFFAOYSA-N

物化性质

• 沸点：
  247.3±30.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯-4-吗啉噻吩并[2,3-d]嘧啶-6-甲醛 、 N-(2-methoxyethyl)-N-methylpiperidin-4-amine 以to give [1-(2-chloro-4-morpholin-4-yl-thieno[2,3-d]pyrimidin-6-ylmethyl)-piperidin-4-yl]-(2-methoxy-ethyl)-methyl amine as a solid, which的产率得到1-((2-chloro-4-morpholinothieno[2,3-d]pyrimidin-6-yl)methyl)-N-(2-methoxyethyl)-N-methylpiperidin-4-amine
  参考文献：
  名称：

  Phosphoinositide 3-kinase inhibitor compounds and methods of use

  摘要：

  公式Ia-d的化合物，其中X为S或O，mor为吗啡啶基团，而R3为单环杂芳基团，包括立体异构体，几何异构体，互变异构体，溶剂化物，代谢物和药学上可接受的盐，对于调节脂质激酶（包括PI3K）的活性以及治疗由脂质激酶介导的癌症等疾病非常有用。本文公开了使用公式Ia-d的化合物进行哺乳动物细胞中的体外，体内和原位诊断，预防或治疗此类疾病或相关病理条件的方法。

  公开号：

  US08383620B2

文献信息

• Pharmaceutical compounds
  申请人：Shutteleworth Stephen

  公开号：US20090131429A1

  公开（公告）日：2009-05-21

  Fused pyrimidines of formula (I): where A is a thiophene or furan ring and R 1 -R 3 and n are defined in the specification. These compounds have activity as inhibitors of PI 3 K and may thus be used to treat diseased and disorders arising from abnormal cell growth, function or behaviour associated with PI 3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  式(I)的融合嘧啶化合物：其中A为噻吩或呋喃环，R1-R3和n在规范中有定义。这些化合物具有抑制PI3K的活性，因此可用于治疗与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和障碍，如癌症、免疫性疾病、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经系统疾病。还描述了合成这些化合物的方法。
• PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Bayliss Tracy

  公开号：US20080242665A1

  公开（公告）日：2008-10-02

  Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R 3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化学式Ia-d的化合物，其中X为S或O，mor为吗啡啶基团，R3为单环杂芳基团，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，可用于调节脂质激酶包括PI3K的活性，并用于治疗由脂质激酶介导的癌症等疾病。本文公开了使用化合物Ia-d的方法，用于哺乳动物细胞中体外、体内诊断、预防或治疗这种疾病或相关病理条件。
• Triazole Derivative or Salt Thereof
  申请人：Murakami Takeshi

  公开号：US20070259854A1

  公开（公告）日：2007-11-08

  [Problem] There is provided a compound which can be used for therapy of diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11β-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.

  [问题] 提供了一种化合物，可用于治疗11β-羟基类固醇脱氢酶1型（11β-HSD1）参与的疾病，特别是糖尿病，胰岛素抵抗。[解决方案的手段] 发现一种三唑衍生物，其中三唑环在2位被三取代甲基基团取代，或其药学上可接受的盐具有强大的11β-HSD1抑制活性。此外，本发明的三唑衍生物表现出优异的降低血糖水平的作用，因此可用于治疗糖尿病，胰岛素抵抗。
• PHARMACEUTICAL COMPOUNDS
  申请人：Shuttleworth Stephen J.

  公开号：US20100280027A1

  公开（公告）日：2010-11-04

  Provided herein are methods of treating diseases or disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, which method includes administering to a patient in need thereof a compound that is a fused pyrimidine of formula (I):

  本文提供了一种治疗因PI3激酶异常细胞生长、功能或行为引起的疾病或紊乱的方法，该方法包括向需要该治疗的患者施用以下化合物的融合嘧啶：(I)。
• TRIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1790641A1

  公开（公告）日：2007-05-30

  [Problem] There is provided a compound which can be used for therapy of diseases in which 11 β-hydroxysteroid dehydrogenase type 1(11β-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11β-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.

  [问题]提供了一种化合物，该化合物可用于治疗 11 β-羟类固醇脱氢酶 1 型(11β-HSD1)参与的疾病，特别是糖尿病、胰岛素抵抗。 [解决方法]研究发现，一种三唑衍生物（其中三唑环在 2 位被三取代甲基取代）或其药学上可接受的盐具有很强的 11β-HSD1 抑制活性。此外，本发明的三唑衍生物具有良好的降低血糖水平的作用，因此可用于治疗糖尿病、胰岛素抵抗。